A 2023 review and meta-analysis found that insulin (and insulin secretagogue) use was associated with an increased pancreatic cancer risk (37), while the use of biguanide and thiazolidinedione (type 2 diabetes medication) carried no risk, or potentially a lower risk of some cancers (37–39). The gene discussed is INS; the disease is familial pancreatic carcinoma.